Introduction
============

The health promoting effects of probiotic bacteria are strain-specific, hence their discrimination and identification is very important and crucial under strain level by applying an efficient and valid strain-identification techniques such as 16S rRNA sequencing. Besides, some identification methods can be utilized for assessment on the safety aspect and ecological properties of probiotics ([@B54]; [@B61]). The choice of appropriate probiotics is the most important base for enhancing the bio-therapeutic achievement in nutraceutical/pharmaceutical products. Several important characters of bacteria used as probiotics are the ability to survive in gastric conditions and adhere to the host intestinal cells ([@B35]; [@B16]). However, *in vitro* procedures for choice of promising probiotics are necessary because *in vivo* methods are costly and need agreement by ethical committees.

Caco-2 cells have been effectively applied to find the mechanism of cellular adhesion of non-pathogenic lactic acid bacteria (LAB; [@B68]). It has also been explained that enterococci produce antimicrobial substances such as bacteriocins, hydrogen peroxide, and lactic acid ([@B62]; [@B23]), which could elucidate their ability against several pathogens such as *Staphylococcus aureus* and *Listeria monocytogenes*. The connection of *Enterococcus* bacteria with human diseases has raised concern regarding their use as probiotic microorganisms ([@B22]). Several enterococcal strains are able to have antiviral activity ([@B70]), beneficial effects in anti-tumoral protective responses ([@B65]) and can restore the microbiota balance in antibiotic-induced dysbiosis ([@B64]). *Enterococcus* bacteria, utilized in fermentation of vegetable products, meat, and dairy, are the reason of clinical infections. Therefore, it is vital to evaluate the virulence genes as well the antibiotic resistance profile.

Although the safety aspect of this genus is still blurred, members of enterococci are now engaged as probiotic bacteria to improve the immunity and human health ([@B7]). The capability of these bacteria to make enterocins is remarkable and can be applied as food bio-preservatives ([@B34]). Bacteriocins are small, ribosomally synthesized and heat-stable peptides that apply antimicrobial activity against pathogenic bacteria or food spoilage, including *Staphylococcus aureus, Clostridium* spp. *Bacillus* spp., *L. monocytogenes*, and *Campylobacter* spp. ([@B47]; [@B39]). [@B23] categorized bacteriocins produced by *Enterococcus* bacteria into four different classes: Class I is lantibiotic enterocins such as cytolysin (CylLL/S; [@B25]); Class II is small, non-lantibiotic enterocins; Class III is cyclic enterocins for instance enterocin AS-48 ([@B20]); and Class IV is large proteins like enterolysin A ([@B31]). There are three subclasses within class II including subclass IIa such as enterocin A and P (Ent A and Ent P), which are pediocin-like bacteriocins; subclass IIb like enterocin L50 and Q (Ent L50A/B and Ent Q), which required two peptides for full antimicrobial activity and subclass IIc like enterocin B (Ent B), which are other linear and non-pediocin-type enterocins ([@B10]).

Although there are rising concern about the safety of *Enterococcus* bacteria because of their relationship with several human infections ([@B7]), a lot of works specify that enterococci play a key function in the improvement of the sensory properties of fermented foods like olives, sausages and cheese ([@B41]). [@B9] elucidated a lot of virulence factors and their actions in *Enterococcus* bacteria ([@B9]). These include the *cylA* which is in charge of the transportation and activation of the cytolisin; *cylB* and *cylM* involved in the post-translational modification; *esp* gene in charge of a cell wall protein involved in immune evasion; *agg* encodes an aggregation protein which is responsible for adherence to eukaryotic cells; *gelE* is in charge of toxin production that hydrolyzes gelatine and other compounds, and finally *cpd, ccf*, and *cad* genes encode sex pheromones, which are in charge of facilitating conjugation.

Because of the high potential of *Enterococcus* bacteria in health and food, the purpose of current study was to find out the antimicrobial activity and the presence of bacteriocin structural genes and virulence factors in *Enterococcus faecium* CM33 isolated from ewe colostrum to assess the potential probiotic properties and safety aspect of use of this strain.

Materials and Methods {#s1}
=====================

Bacteria Isolation
------------------

*Enterococcus faecium* CM33 was isolated from ewe colostrum by culturing in de Man Rogosa and Sharpe broth (MRS) and following incubation of 50 μl of cultured medium onto MRS agar supplemented with 6.5% (w/v) NaCl (MRS-NaCl) for 18 h at 37°C in aerobic conditions. After enrichment, five passages by isolated colony, the pure bacterium isolate was obtained.

PCR Amplification of Isolate
----------------------------

The amplification of 16S rRNA gene (1500 bp) of the isolate was performed by the primers (F 5′-AGAGTTTGATC CTGGCTCAG-3′ and R 5′-GGCTGCTGGCACGTAGTTAG-3′), which those primarily used by [@B37]. The amplification reaction was performed in a thermocycler (Thermo Electron Corporation, Waltham, MA, USA) with the following thermocycle program: Four min at 96°C as an initial denaturation; 30 s at 96°C as a denaturation for 30 cycles; 30 s at 48°C as an annealing and 45 s at 72 C as an extension, with a final extension step for 4 min at 72°C. The total volume of reaction was 50 μl. The PCR product was visualized through 0.8% (w/v) agarose gel (Sigma Chemical Co., Poole, UK) electrophoresis by using ethidium bromide staining ([@B37]). PCR product was sequenced by the Macrogen DNA Sequencing Service (Korea). The sequence was interrogated through the BLAST search of the NCBI database. The isolate was identified on account of the highest matching score.

Effects of Heat, pH, and Hydrolytic Enzymes
-------------------------------------------

This strain was cultured in MRS broth for 18 h at 37°C. After 10 min centrifugation at 12000 g, cells were removed and the cell free supernatant (metabolites) was utilized for additional characterization. To determine the effect of pH on the metabolites action, pH of the crude supernatant was adjusted in the range between 1.5 and 9 by adding sterile 1 M HCl or 1 M NaOH. Sample was incubated at room temperature for 4 h. Thermostability of metabolites was determined at diverse temperatures. Crude supernatant was autoclaved at 121°C for 15 min and then incubated at different temperatures (4, -20, and -70C) for 24 h, 48 h, 2 weeks, and 1 month.

The sensitivity of cell free supernatant toward different proteolytic enzymes, amylase, and catalase was investigated. One mg/ml of enzymes including proteinase K, pronase E, trypsin, and chymotrypsin were prepared in 15 mM sodium phosphate buffer (pH 7.2) and pepsin was prepared in glycine buffer pH 2. Before incubating for 2 h at 37°C, proteases at a final concentration of 0.1 mg/ml were added. The crude cell free supernatant was treated with catalase at 0.1 mg/ml to remove potential inhibitory effects because of production of hydrogen peroxide.

Targeting Bacteriocin Genes
---------------------------

To detect genes encoding the known enterocins, genomic DNA of strain CM33 was used as template. PCR were performed in a Hybrid PCR Sprint thermocycler (Thermo Electron Corporation, Waltham, MA, USA) in 20 ml reaction mixture (10 pmoles of each primer, 1 mL DNA template, and 1.25 U Taq polymerase). The PCR conditions for enterocin-encoded genes are illustrated in **Table [1](#T1){ref-type="table"}**. The PCR products were visualized by electrophoresis in 1.5% agarose gels.

###### 

Primer sequences for PCR amplification of enterocin genes in *Enterococcus faecium* CM33.

  ----------------------------------------------------------------------------------------------------------
  Genes    Primers      Sequences 5′→3′                Size (bp)   Tm (°C)   PCR amplification   Reference
  -------- ------------ ------------------------------ ----------- --------- ------------------- -----------
  A\       EntA-F\      AAATATTATGGAAATGGAGTGTAT\      475\        56\       --\                 [@B17]\
  \        EntA-R\      CTCGTTAAGGTCCCTTCACG\          \           \         \                   \
  B\       EntB-F\      CAAAATGTAAAAGAATTAAGTACG\      201\        56\       --\                 [@B15]\
  \        EntB-R\      AGAGTATACATTTGCTAACCC\         \           \         \                   \
  P\       P-F\         GCTACGCGTTCATATGGTAATGGT\      132\        60\       --\                 [@B11]\
  \        P-R\         ATGTCCCATACCTGCCAAACCAGAAGC\   \           \         \                   \
  X\       EntX-F\      GTTTCTGTAAAAGAGATGAAAC\        500\        50\       +\                  [@B19]\
  \        EntX-R\      CATACCAATTACTAATTCTCC\         \           \         \                   \
  31\      Ent31-F\     CCTACGTATTACGGAAATGGT\         130\        58\       +\                  [@B15]\
  \        Ent31-R\     GCCATGTTGTACCCAACCATT\         \           \         \                   \
  Q\       EntQ-F\      CAAGAAATTTTTTCCCATGGC\         95\         55\       +\                  [@B12]\
  \        EntQ-R\      ACGCTATGGTAAAAATTCTTC\         \           \         \                   \
  AS48\    EntAS48-F\   GAGGAGTTTCATGATTTAAAG\         185\        50\       --\                 [@B17]\
  \        EntAS48-R\   CGAACCATTAAATTGTTATAC\         \           \         \                   \
  *Cyl*\   Cyl-F\       GGCGGTATTTTTACTGGAGTN\         248\        58\       +\                  [@B15]\
  \        Cyl-R\       CCTACTCCTAAGCCTATGGTA\         \           \         \                   \
  L50A     EntL50-F\    GGAGCAATCGCAAAATTAG\           150         55        --                  [@B17]
           EntL50-R     TAACCTCTTCCTACCCGTTA                                                     

  ----------------------------------------------------------------------------------------------------------

Bile Tolerance Test
-------------------

The method previously described by [@B54] was used to measure the viability of strain in bile salt. The isolate was grown in MRS medium supplemented with 0.5% (w/v) oxgall then was incubated for 4 h at 37°C. To determine of cell count, aliquots were plated onto MRS-agar medium at times 0, 1, 3, and 4 h. Control tube was without bile salt ([@B54]).

Survivability in Simulated *In Vitro* Digestion
-----------------------------------------------

Simulated *in vitro* digestion was carried out to evaluate the survival rate of strain CM33 in similar condition of the human gastrointestinal tract. To simulate the stomach digestion, samples (pH 3.0) were treated with 5% (w/v) pepsin (Sigma Chemical Co., Poole, UK) then were incubated for 120 min at 37°C with gentle agitation. The intestinal digestion was simulated by inoculating solutions of 0.1% (w/v) pancreatin (Sigma Chemical Co., Poole, UK) and 0.3% (w/v) bile oxgall. The samples were incubated for 180 min at 37°C with gentle shaking. Samples were removed before and after gastric and intestinal digestion to measure cell count. The serially diluted aliquots were cultured on MRS agar medium and were incubated for 24 h under anaerobic conditions ([@B59]).

Adhesion Ability to Caco-2 Cells
--------------------------------

Caco-2, the colon adenocarcinoma cell line, was used to evaluate the adhesion ability of *E. faecium* CM33 to human epithelial cells. RPMI medium supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) penicillin/streptomycin mixture (Sigma Chemical Co., Poole, UK) was used to culture human colon cancer cells. Cells were seeded on 24-well tissue culture plates and incubated at 37°C in 5% CO~2~ in a humidified atmosphere. Before the adhesion assay, fresh antibiotic-free RPMI was used to wash wells, which have a monolayer of Caco-2 cells. Then, each well was inoculated with 1 × 10^7^ cfu/ml of *E. faecium* in a total volume of 1 ml and incubated at 37°C for 3 h in an atmosphere of 5% (v/v) CO~2~. The wells were washed thrice with a pre-warmed phosphate buffer saline (Sigma Chemical Co., Poole, UK) to remove non-attached cells of *E. faecium*. To detach the cells, 1 ml of 1% Triton X-100 (Sigma Chemical Co., Poole, UK) was added to each well with gently stirring for 5--10 min and then the viable human colon cancer cells, Caco-2, were counted. Finally, bacteria and Caco-2 cells were cultured onto MRS agar by the pure plate method and incubated at 37°C anaerobically. The total number of bacteria attached to viable Caco-2 cells expressed as bacterial adhesion and carried out in triplicate.

Inhibition of Pathogen Adhesion to Caco-2 cells
-----------------------------------------------

Caco-2, human colon cells, were used to assess the effect of *E. faecium* treatment on the pathogen interaction with cells. *E. faecium* and pathogens (*Escherichia coli, S. flexneri, K. pneumonia*, and *S. aureus*) were cultured in MRS and LB, respectively. Overnight culture of *E. faecium* and pathogens were harvested and washed thrice with phosphate buffer saline. Bacteria were diluted in antibiotic-free RPMI and 0.5 ml/well (10^8^ CFU per well) of *E. faecium* suspension was inoculated to 24-well tissue culture plates. To evaluate the capability of *E. faecium* to restrain pathogenic bacteria adhesion to Caco-2 cells, simultaneous addition of 10^8^ CFU per well of tested pathogens was performed separately. Plates were incubated 1 h at 37°C and washed twice with sterile PBS then 1% (v/v) Triton X-100 (Sigma Chemical Co., Poole, UK) in deionized water for 5 min was used to lyse the cell-associated pathogens. To find out the number of viable cell-linked bacteria by colony forming counts, the suitable dilutions of the lysate were placed on LB agar. The inhibition analysis was calculated in three independent trials and each experiment was carried out in triplicate.

Antimicrobial Activity
----------------------

To determine and identify inhibitory substances of metabolites produced by *E. faecium* CM33, well-diffusion method was performed ([@B30]). Overnight cultures of the indicator strains were cultured in MRS agar at 37°C for 18 h. 50 μl of filtered crude supernatant of CM33 were dropped to each well (5 mm) into agar plates. The suspensions were inoculated to the wells and permitted to diffuse for 4 h at room temperature into MRS agar. The inhibition zone produced around the wells was determined after 24 h incubation at the optimum growth temperature of the indicator strains. The diameter of the produced inhibition zones around the wells was determined by digital caliper. These diameters were classified to four different groups including no inhibition (--), weak (+), good (++), and strong (+++). All trials were carried out in triplicate.

PCR Detection of Virulence Factors in Enterococci
-------------------------------------------------

Detection of genes encoding potential virulence factors in *E. faecium* CM33 was performed by PCR. Total bacterial DNA used as template in PCR reactions was isolated by the alkaline lysis method ([@B3]). Virulence genes evaluated in this study include: cytolysin (CylA, CylB, CylM; [@B60]; [@B69]), enterococcal surface protein (esp; [@B69]), collagen-binding protein (ace; [@B50]), gelatinase (gelE), aggregation substance (agg; [@B18]; [@B2]), sex pheromone peptides (cpd; [@B1]), cell-wall anchored collagen adhesion (acm; [@B8]; [@B42]), and van A, van B, van C2 ([@B58]). *E. faecium* ATCC 51299 and ATCC 29212 were controls for this test. PCR was used to detect of genes encoding these factors using several primers (**Table [2](#T2){ref-type="table"}**) which have been described by [@B18].

###### 

Primers used for screening of virulence factors genes.

  ----------------------------------------------------------------------------------------
  Gene         Primer          Sequence 5′→3′              Product size (bp)   Reference
  ------------ --------------- --------------------------- ------------------- -----------
  *CylA*       cytI\           ACTCGGGGATTGATAGGC\         688                 [@B69]
               cytIIb          GCTGCTAAAGCTGCGCTT                              

  *CylB*       cytB1\          AAGTACACTAGTAGAACTAAGGGA\   2020                [@B60]
               cytB2           ACAGTGAACGATATAACTCGCTATT                       

  *CylM*       cylM1\          AAAAGGAGTGCTTACATGGAAGAT\   2940                [@B60]
               cylM2           CATAACCCACACCACTGATTCC                          

  *esp*        esp14F\         AGATTTCATCTTTGATTCTTGG\     510                 [@B69]
               esp12R          AATTGATTCTTTAGCATCTGG                           

  *ace*        ace-F\          GAATTGAGCAAAAGTTCAATCG\     1008                [@B4]
               ace-R           GTCTGTCTTTTCACTTGTTTC                           

  *gelE*       gelE-F\         ACCCCGTATCATTGGTTT\         419                 [@B56]
               gelE-R          ACGCATTGCTTTTCCATC                              

  *agg*        agg-F\          AAGAAAAAGAAGTAGACCAAC\      1553                [@B18]
               agg-R           AAACGGCAAGACAAGTAAATA                           

  *cpd*        cpd-F\          TGGTGGGTTATTTTTCAATTC\      782\                [@B56]
               cpd-R           TACGGCTCTGGCTTACTA                              

  *van A*      van *C~2~-*1\   CGGGGAAGATGGCAGTAT\         732                 [@B58]
               van *C~2~-*2    CGCAGGGACGGTGATTTT                              

  *van B*      van *C~2~-*1\   CGGGGAAGATGGCAGTAT\         635                 [@B58]
               van *C~2~-*2    CGCAGGGACGGTGATTTT                              

  *van C~2~*   van *C~2~-*1\   CGGGGAAGATGGCAGTAT\         484                 [@B58]
               van *C~2~-*2    CGCAGGGACGGTGATTTT                              
  ----------------------------------------------------------------------------------------

Interpretation of Results
-------------------------

Data were analyzed using SPSS 19.0 software (SPSS Inc., an IBM Company, Schaumburg, IL, USA). One-way ANOVA followed by multiple mean comparisons Duncan's test were used to assess statistical differences in multiple groups. Values are mean ± SE and *p* ≤ 0.05 is considered statistically significant.

Results
=======

Bacteria Isolation
------------------

Screening of different dairy products like colostrum, yogurt, curd, cheese, and yogurt drink led to the isolation of *E. faecium* CM33 from ewe colostrum. After DNA extraction, the 16S rRNA fragments were amplified by PCR. According to 16S rRNA identification, 50 of the isolated bacteria were classified into three major groups of LAB, namely, 14% enterococci, 66% lactobacilli, and 20% lactococci. The isolates classified as LAB were also separated and identified by sequencing. After sequencing, the *Enterococcus* strains were categorized into *E. lactis, E. hirae, E. avium, E. durans, E. faecalis*, and *E. faecium*. The *Lactobacillus* strains representing 66% were classified into *L. acidophilus* and *L. plantarum*. The *Lactococcus* species were classified only into one species (*Lactococcus lactis*). Probiotic characterization of these isolates showed that *E. faecium* CM33 has the best properties such as tolerance to acid and bile, antimicrobial activity and antibiotic resistance thus it was selected for further analysis.

Effects of pH, Heat, and Hydrolytic Enzymes on *E. faecium* Bacteriocin
-----------------------------------------------------------------------

The stability and activity of *E. faecium* CM33 bacteriocins has been shown in **Table [3](#T3){ref-type="table"}**. Bacteriocins were active over broad ranges of pH from 1.5 to 9. It was also stable after autoclaving at 121°C for 15 min. The treatment of cell free supernatant of *E. faecium* CM33 with amylase, catalase, and proteolytic enzymes showed that amylase and catalase enzymes do not influence on the bacteriocin activity, while proteolysis enzymes affect on the bacteriocin activity after 2 h.

###### 

Effects of pH, heat, and enzymes (concentration 1 mg/ml) on the antibacterial activity present in *E. faecium* CM33 culture metabolites.

  ---------------------------------------------
  Treatments           Antibacterial activity
  -------------------- ------------------------
  **pH**\              \
  1.5--9\              +\
  **Heat**\            \
  121° C for 15 min\   +\
  **Enzymes**\         \
  Pepsin\              --\
  Trypsin\             --\
  Chymotrypsin\        --\
  Proteinase K\        +\
  Pronase E\           +\
  Catalase\            --\
  Amylase              --

  ---------------------------------------------

PCR Analysis of Bacteriocin Genes
---------------------------------

PCR amplification using specific primers as shown in **Table [1](#T1){ref-type="table"}** was used to screen DNA of *E. faecium* CM33 for the existence of the known enterocin genes. This study focused on enterocin genes including *Cyl*, A, P, 31, Q, X, L50A, and AS-48. *E. faecium* CM33 showed four bands: 95, 130, 248, and 500 bp corresponding to the specific amplification of enterocins Q, 31, *Cyl*, and X, respectively.

Survivability in Bile Salt and Simulated Digestion
--------------------------------------------------

*Enterococcus faecium* CM33 was incubated in 0.3% bile salts for 4 h. It showed the survival rate of \>93% after this incubation period. One of the most desirable features needed for probiotics is the ability to survive in the GI tract. For further analysis, *E. faecium* CM33 was evaluated using simulated digestion test. This test revealed that this strain had 57.6% digestion survivability.

Adhesion Assay to Caco-2 Cells
------------------------------

The strain was tested further for its capability to colonize Caco-2 cells. *E. faecium* CM33 showed the acceptable adhesion ability with an adhesion value of 32 × 10^4^ cfu/ml. *E. faecium* ATCC 29212, which used as a control to compare their adhesion ability, could not significantly adhere to Caco-2 cells.

Inhibition of Pathogens Adhesion
--------------------------------

In the presence of *E. faecium* CM33, the inhibition of pathogens adhesion was presented in **Table [4](#T4){ref-type="table"}**. All the adherent pathogens were clearly reduced by co-culture with *E. faecium*. The reduction of *E. coli, S. flexneri, K. pneumoniae*, and *S. aureus* adhesion to Caco-2 cells was more than 50% added with *E. faecium* 10^8^ CFU per well.

###### 

Inhibition of pathogens adhesion by co-culture with *E. faecium* CM33.

  -------------------------------------------------------------------------------------------
  Pathogens                         Adhesive pathogen count (10^5^ CFU ml^-1^)   
  --------------------------------- -------------------------------------------- ------------
  *Clostridium difficile*\          5.3 ± 0.4\                                   3.7 ± 0.3\
  *Clostridium histolyticum*\       3.8 ± 0.2\                                   2.8 ± 0.4\
  *Staphylococcus aureus*\          3.4 ± 0.3\                                   1.1 ± 0.2\
  *Staphylococcus saprophyticus*\   4.6 ± 0.2\                                   3.2 ± 0.3\
  *Salmonella typhimurium*\         7.1 ± 0.3\                                   4.8 ± 0.4\
  *Candida albicans*\               6.4 ± 0.4\                                   3.6 ± 0.3\
  *Escherichia coli 0157*\          8.5 ± 0.2\                                   3.8 ± 0.2\
  *Bacillus cereus*\                6.6 ± 0.3\                                   4.0 ± 0.4\
  *Listeria monocytogenes*\         5.4 ± 0.2\                                   2.5 ± 0.2\
  *Klebsiella pneumoniae*\          8.3 ± 0.4\                                   4.1 ± 0.3\
  *Shigella flexneri*\              4.9 ± 0.3\                                   1.3 ± 0.4\
  *Pseudomonas aeroginosa*\         5.2 ± 0.2\                                   3.7 ± 0.3\
  *Streptococcus mutans*            4.4 ± 0.4                                    2.7 ± 0.2

  -------------------------------------------------------------------------------------------

Values are mean ± SE.

Antimicrobial Activity
----------------------

The strain CM33 isolated from colostrum displayed antimicrobial activity against all the tested indicator microorganisms (**Table [5](#T5){ref-type="table"}**). The most sensitive indicators were *L. monocytogenes*, followed by *Candida albicans*. On the contrary, *Clostridium difficile, Clostridium histolyticum, Salmonella typhimurium*, and *Streptococcus mutans* were the less sensitive indicator microorganisms.

###### 

The antimicrobial activity of *E. faecium* CM33 against pathogens.

  -------------------------------------------------------------
  Pathogenic microorganisms         Source        Supernatant
  --------------------------------- ------------- -------------
  *Clostridium difficile*\          ATCC 43255\   \+\
  *Clostridium histolyticum*\       ATCC 19401\   +\
  *Staphylococcus aureus*\          ATCC 25923\   ++\
  *Staphylococcus saprophyticus*\   PTCC 1440\    ++\
  *Salmonella typhimurium*\         ATCC 14028\   +\
  *Candida albicans*\               ATCC 10231\   +++\
  *Escherichia coli 0157*\          PTCC 1276\    ++\
  *Bacillus cereus*\                ATCC 11778\   ++\
  *Listeria monocytogenes*\         PTCC 1163\    +++\
  *Klebsiella pneumoniae*\          ATCC 10031\   ++\
  *Shigella flexneri*\              PTCC 1234\    ++\
  *Pseudomonas aeroginosa*\         PTCC 1181\    ++\
  *Streptococcus mutans*            ATCC 35668    +

  -------------------------------------------------------------

Virulence Genes
---------------

The presence of virulence genes in genomic DNA of *E. faecium* CM33 was screened by PCR. Currently several enterococci are being used as probiotics but they should be carefully assessed to ensure that they are not pathogenic. *E. faecium* CM33 was found to be negative for all tested virulent genes (**Table [6](#T6){ref-type="table"}**). In the case of van A, van B and van C~2~ genes, it is essential to note that this result associate with the lack of resistance to vancomycin.

###### 

Detection of virulence-related genes in enterococcal strains used in this research.

  -------------------------------------------------------
  Strain        Species         Virulent genes
  ------------- --------------- -------------------------
  ATCC 29212\   *E. faecium*\   *gelE, cylA*\
  ATCC 51299\   *E. faecium*\   *gelE, vanB, ccf, agg*\
  CM33          *E. faecium*    None

  -------------------------------------------------------

Discussion
==========

The food industry is requested to present increasingly functional foods containing beneficial components because of the great interest on health-oriented nutritional habits. Bacteria generally recognize as probiotic commonly belong to LAB. These microorganisms, as commensals in the human gastrointestinal tract, show a long history of use in foods and fermented products ([@B26],[@B27], [@B29]; [@B43],[@B44],[@B45]). *Enterococcus* bacteria have various helpful functions in the dairy industry ([@B28]; [@B46]). As starters, enterococci fulfill a considerable function in developing flavor progress and quality of cheeses. As probiotics, LAB are able to be used for healing of gut disorders in both humans and animals since these bacteria contribute to the intestinal health of the host by the development of gut microbial balance ([@B55]). On the other hand, some requirements should be fulfilled to introduce a certain strain as a probiotic ([@B14]) and probiotic activities should be confirmed in well-made human studies. The aim of this paper was to evaluate safety and the potential beneficial properties of *E. faecium* CM33 isolated from ewe colostrum.

The most important characteristics required for microorganisms to be probiotics is their ability to survive while passing through the upper digestive tract to reach the large intestine, where their positive functions are predictable ([@B6]; [@B67]; [@B48]). Probiotics can adhere to epithelial cells and should tolerate high acidic pH and high bile salt conditions in the gastric and intestinal fluid. Resistance to acid is of the popular properties used during the screening of potential probiotic strains. Another important mechanism in resisting intestinal pathogens and preventing diseases is the competition of probiotic bacteria with pathogens to adhere and colonize ([@B53]). In this study, *E. faecium* CM33 isolated from ewe coloctrum dairy products was capable to survive both in bile salts and the gastric simulated digestion condition. This strain was further evaluated for their adhesion ability to Caco-2 cells. Data showed that *E. faecium* CM33 possessed an ability to resist the digestion conditions and was able to adhere to Caco-2 cells. These results show that *E. faecium* CM33 could be a suitable candidate to be as potential new probiotic.

The production of antimicrobial compounds like bacteriocins, organic acids, and hydrogen peroxide is of the well-designed properties applied to characterize probiotics ([@B55]). Production of bacteriocins (enterocins) is the useful biotechnological trait of *Enterococcus* bacteria ([@B22]). The PCR results (**Table [1](#T1){ref-type="table"}**; **Figure [1](#F1){ref-type="fig"}**) showed that *E. faecium* CM33 carried enterocins A, 31, Q, and X structural genes, while the other primers used in this test did not yield any visible band. [@B23] classified enterocins A and 31 in the class IIa bacteriocins (pediocin-like bacteriocins). This group of bacteriocins is cationic and shows very effectual anti-*Listeria* activity and permeabilizes the cell membrane to kills target cells. Moreover, results showed that *E. faecium* CM33 has the greatest inhibitory function against *L. monocytogenes*. This fact could be described by the capability of *Enterococcus* bacteria to obtain and replace genetic information by conjugation ([@B7]), not only between strains of *Enterococcus* genus, but also with other genera ([@B63]).

![**Amplification results for screening enterocin genes in *Enterococcus faecium* CM33.** L, molecular weight ladder (kbp); N, negative control; P, positive control by using purified DNA from a producer strain; Q, enterocin Q; 31: enterocin 31; A: enterocin A and X: enterocin X.](fmicb-06-00782-g001){#F1}

The class IIb bacteriocins, two-peptide bacteriocins, also need two diverse peptides (enterocins Q and X) for activity. The production of multiple bacteriocins is not unusual and could be a general aspect of enterococci. Many *Enterococcus* bacteria are able to produce multiple bacteriocins, such as *E. faecium* WHE81 ([@B21]), *E. faecium* KV-B5 ([@B32]), *E. faecium* NKR-5-3A ([@B33]), *E. faecium* JCM 5804T ([@B52]), and *E. faecium* DAC2 ([@B57]). Nevertheless, the incidence of numerous enterocin genes in enterococci does not forever link with an advanced bacteriocin activity in their supernatants and not all enterocin genes should be expressed at the same time ([@B10]).

*Enterococcus faecium* is the most normally occurring enterococcal species in dairy industry ([@B40]) and fermented vegetable ([@B38]). This species is also found in raw fruits ([@B1]) and probiotic preparations ([@B61]). However the nosocomial infections related to wound, bacteraemia, urinary-tract infections, and abdominal infections are caused by many enterococcal species ([@B66]). *Enterococcus* bacteria, as pathogens, have intrinsic and acquired resistance to many antibiotics that were considered as a major concern. The resistance against antibiotics and the production of virulence factors are two significant factors for the assessment of safety in enterococci. Probiotic strains may harbor antibiotic resistance genes that are able to be transferred to pathogenic bacteria. In particular, the most significant concern among antibiotic resistance is vancomycin resistance since it is the last antibiotics largely efficient against clinical infections by multidrug-resistant pathogens ([@B36]). Several studies elucidated the incidence of vancomycin-resistant enterococci in food of animal origin, mainly in *E. faecium* and *E. faecalis* species; although the isolation frequency seems to be lower than in clinical samples ([@B36]). In our case, CM33 strain was found to be susceptible to vancomycin, and this lack of resistance associated with the absence of van A, van B and van C~2~ genes. According to the EFSA, if the strain has one or more these genetic elements, this strain is unsafe and could not be applied as a feed additive ([@B49]). Moreover, no resistance to other antibiotics such as gentamycin, erythromycin, tetracycline, and rifampicin was detected in this colostrum-isolated *Enterococcus*.

The potential pathogenicity of CM33 strain was evaluated by assessing the existence of genes encoding for other virulence factors, as determined by studies in various enterococcal species ([@B50]). Genes encoding for cell-wall anchored collagen adhesion (*acm*), aggregation substance (*agg*), cytolysin (*cylA*), and gelatinase (*gelE*) were not found in our isolated strain. Besides, the amplification for a sex pheromones gene (*ccf*), which could be involved in initiating conjugation processes ([@B13]) was negative.

One of important properties of strain to be as a potential probiotic is anti-pathogen activity. *In vitro* test under neutralized pH was performed using 13 pathogenic microorganisms and supernatants (metabolites) obtained from the exponential *E. faecium* CM33 culture. The well diffusion technique was performed to evaluate the inhibitory effect of the CM33 strain against 13 pathogenic microorganisms. The *E. faecium* supernatant demonstrated the strong inhibition function against indicator pathogens (**Table [5](#T5){ref-type="table"}**). This strain was found to have the strongest inhibition activity against *L. monocytogenes* and *Candida albicans*. It was recommended that *E. faecium* CM33 produced bacteriocins (enterocin A and 31) to inhibit these pathogens.

According to previous studies, the multiple enterocins-producing isolate is likely more capable and could display a wider range of inhibition in inhibiting the growth of undesirable bacteria than a simple bacteriocin producer ([@B33]). *E. faecium* DAC2 (producer both Ent A and Ent P) produces a higher antagonistic activity than those of the controls *E. faecium* T136 and *E. faecium* P13 (producer of enterocin A and enterocin P, respectively; [@B57]). The production of bacteriocins by LAB helps LAB to be colonized in their habitats and to compete with other bacteria ([@B24]). Many factors including decreased pH levels, competition for substrates, and the production of substances such as bacteriocins are caused the antimicrobial activity of LAB ([@B51]).

The competitive inhibition of enteropathogen attachment to epithelial cells by LAB is another important factor. So, the competitive inhibition of adherence of pathogenic bacteria to Caco-2 cells by adhering *E. faecium* CM33 cells was evaluated. This strain was able to strongly inhibit the adhesion of many tested pathogens (**Table [4](#T4){ref-type="table"}**). However, the mechanisms by which LAB inhibit pathogen adhesion to human cell lines *in vitro* are not fully understood. Steric hindrance rather than blockage of specific receptors may be involved ([@B5]). Additional trials are required to discover the exact mechanism of inhibition observed in this study.

Conclusion
==========

An identified strain of *E. faecium* from colostrum can present interesting probiotic characteristics. It can stay alive during passing the digestive system and has ability to be colonized on the intestinal epithelial cells. In addition, this strain showed a significant enteropathogen growth inhibiting activity and interference with pathogens adhesion to human colon Caco-2 cells. These features could enable this strain to establish itself in the intestinal tract and to compete with other bacterial species. However, the safety and implications for public health of individual enterococcal strains must be carefully evaluated to fully exploit their industrial potential.
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